This month's edition of Diagnostic Imaging includes a discussion that comes close to being a point-counterpoint on the merits of third-party utilization review. Articles by Dr. Michael S. Komarow and Dr. James H. Thrall (page 21) debate the use of third-party utilization review as a way to control spiraling imaging costs.
This month's edition of Diagnostic Imaging includes a discussion that comes close to being a point-counterpoint on the merits of third-party utilization review. Articles by Dr. Michael S. Komarow and Dr. James H. Thrall (page 21) debate the use of third-party utilization review as a way to control spiraling imaging costs.
Komarow's article is actually a response to one by Thrall that appeared in the July issue of Diagnostic Imaging ("Utilization management steps onto center stage," page 29, and on the Internet at www.diagnosticimaging.com's July issue posting). Based on the strong response to that article, we agreed to run Komarow's rejoinder and offered Thrall an opportunity to prepare a reply. Taken together, the three articles provide what I think is one of the best discussions of this topic I have seen in some time.
The contrast of opinions is a strategy we use in news articles and one that works well in commentary articles as well. It is an article of faith in journalism-and in other areas such as law and government-that in the clash of viewpoints the truth is often found. I won't claim that we've found truth, but I do believe we have focused a bright light on this topic.
The topic is important-physicians tend not to like anyone second-guessing their decisions-and that importance is growing, mainly because insurers of all stripes are looking for ways to control imaging costs. Whether you believe that outside companies should step in and take control or that utilization control questions are best worked out between referring clinicians and radiologists, I think you'll find the articles enlightening.
John Hayes is editor of Diagnostic Imaging.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.